6 Results for "

CCR8+ Treg

" in MedChemExpress (MCE) Product Catalog:
Products (6)

6 Results for "CCR8+ Treg" in MCE Product Catalog:

  • Targets Recommended:
2
2 Cited Publications
Cat. No.: HY-119217
CAS No.: 929300-19-6
Purity:  99.65%
Target:  

CCR

AZ084 is a potent, selective, allosteric and oral active CCR8 allosteric antagonist, with a Ki of 0.9 nM. Has potential to treat asthma . AZ084 restrains the formation of the immunologically tolerant pre-metastatic niche (PMN) and tumor cells metastasis in lung by downregulating Treg differentiation. AZ084 can be used in studies of asthma and cancer .
loading...
    loading...
Cat. No.: HY-P991944

Target:  

CCR

Research Areas:  

Cancer

ZL-1218 is a selective humanized IgG1 antibody, targeting CCR8. ZL-1218 induces antibody-dependent cellular cytotoxicity (ADCC), leading to NK cell-mediated depletion of CCR8-expressing regulatory T cells (Tregs). ZL-1218 blocks the binding of the CCR8 ligand CCL1 to CCR8 and reduces Treg recruitment by inhibiting the chemotaxis of CCR8 + cells. ZL-1218 reduces intratumoral Treg levels in a dose-dependent manner. ZL-1218 exerts enhanced antitumor activity when combined with the anti-PD-1 antibody. ZL-1218 can be used for solid tumour research .
loading...
    loading...
Cat. No.: HY-P991942A
Synonyms: BAY3375968 (FUT8-KO); TPP-23411 (FUT8-KO)

Target:  

CCR

Research Areas:  

Cancer

Lanerkitug (FUT8-KO) (BAY3375968 (FUT8-KO)) is an anti-CCR8 monoclonal antibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the ADCC effect of the antibody. Lanerkitug (HY-P991942) selectively depletes human CCR8+Tregs via antibody dependent cellular cytotoxicity (ADCC) and antibody dependent cellular phagocytosis (ADCP). Lanerkitug can be used in the research of solid tumors .
loading...
    loading...
Cat. No.: HY-P991942
Synonyms: BAY3375968; TPP-23411

Target:  

CCR

Research Areas:  

Inflammation/Immunology Cancer

Lanerkitug (BAY3375968) is a fully human monoclonal IgG1 anti-human CCR8 antibody. Lanerkitug selectively depletes human CCR8 + Tregs via antibody dependent cellular cytotoxicity (ADCC) and antibody dependent cellular phagocytosis (ADCP). Lanerkitug can be used in the research of solid tumors .
loading...
    loading...
Cat. No.: HY-P992365

Target:  

CCR

Research Areas:  

Cancer

HFB101110 is a human-derived inhibitor and Treg depleter that specifically targets CCR8. It does not bind to the homologous CCR4 receptor and is mainly used in research on solid tumors, renal cell carcinoma and colorectal cancer. HFB101110 blocks hCCL1 binding by interacting with the N-terminal extracellular domain of hCCR8, thereby inhibiting hCCL1-induced calcium influx, chemotaxis and downstream signaling pathways. Meanwhile, HFB101110 can mediate ADCC effects to specifically deplete CCR8-positive cells, including intratumoral Tregs. HFB101110 exhibits favorable anti-tumor activity and pharmacokinetic properties .
loading...
    loading...
Cat. No.: HY-184668
Target:  

CCR

Research Areas:  

Inflammation/Immunology

CCR8 agonist 2 is a selective CCR8 agonist with an EC50 of 0.008 μM. CCR8 agonist 2 activates CCR8 + activity in a humanized graft-versus-host disease mouse model. CCR8 agonist 2 can be used for the research of autoimmune diseases .
loading...
    loading...